Investigation of Trends in the Research on Transferrin Receptor-Mediated Drug Delivery via a Bibliometric and Thematic Analysis

This study systematically reviews and characterizes the existing literature on transferrin/transferrin receptor-mediated drug delivery. Transferrin is an iron-binding protein. It can be used as a ligand to deliver various proteins, genes, ions, and drugs to the target site via transferrin receptors for therapeutic or diagnostic purposes via transferrin receptors. This study is based on a cross-sectional bibliometric analysis of 583 papers limited to the subject areas of pharmacology, toxicology, and pharmaceutics as extracted from the Scopus database in mid-September 2022. The data were analyzed, and we carried out a performance analysis and science mapping. There was a significant increase in research from 2018 onward. The countries that contributed the most were the USA and China, and most of the existing research was found to be from single-country publications. Research studies on transferrin/transferrin receptor-mediated drug delivery focus on drug delivery across the blood-brain barrier in the form of nanoparticles. The thematic analysis revealed four themes: transferrin/transferrin receptor-mediated drug delivery to the brain, cancer cells, gene therapy, nanoparticles, and liposomes as drug delivery systems. This study is relevant to academics, practitioners, and decision makers interested in targeted and site-specific drug delivery.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:14

Enthalten in:

Pharmaceutics - 14(2022), 12 vom: 23. Nov.

Sprache:

Englisch

Beteiligte Personen:

Kaur, Tarnjot [VerfasserIn]
Upadhyay, Jyoti [VerfasserIn]
Pukale, Sudeep [VerfasserIn]
Mathur, Ashish [VerfasserIn]
Ansari, Mohd Nazam [VerfasserIn]

Links:

Volltext

Themen:

Bibliometric analysis
Drug delivery
Journal Article
Performance analysis
Review
Scientific mapping
Thematic analysis
Transferrin receptor

Anmerkungen:

Date Revised 27.12.2022

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/pharmaceutics14122574

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM350705895